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PCongenital Heart Disease
evice Closure Rates of Simple Atrial
eptal Defects Optimized by the STARFlex Device
lan W. Nugent, MBBS, Amy Britt, MA, Kimberlee Gauvreau, SCD,
ary E. Piercey, BS, James E. Lock, MD, FACC, Kathy J. Jenkins, MD, MPH, FACC
oston, Massachusetts
OBJECTIVES This study sought to review the outcomes of 3 generations of closure devices for secundum
atrial septal defects (ASDs) at a single institution.
BACKGROUND Transcatheter closure of ASDs is now increasingly performed with devices that have been
modified over time to improve performance.
METHODS A review of prospective clinical trials of Clamshell (C.R. Bard Inc., Murray Hill, New Jersey),
CardioSEAL (NMT Medical Inc., Boston, Massachusetts), and STARFlex (NMT Medical
Inc.) closure devices for simple ASDs was performed. The entry criteria for these trials were
age 2 years, isolated secundum ASD, evidence of right ventricular volume overload, and
maximum stretched diameter varying from 20 to 25 mm. Successful outcomes were defined
as no more than small residual leak (2 mm) with absence of a severe complication or the
need for an additional device or surgery.
RESULTS A total of 72 Clamshell, 30 CardioSEAL, and 42 STARFlex devices were placed in
uncomplicated ASDs. Each device modification resulted in improved closure rates, with the
STARFlex device achieving a 93% complete closure rate with a device/stretched diameter
ratio significantly smaller than with the other devices (p  0.001). Severe complications
occurred in 5 Clamshell, 1 CardioSEAL, and 0 STARFlex cases. Successful outcomes
increased for each generation of device (79%, 93%, and 98% respectively, p  0.009). There
have been no long-term complications for either the CardioSEAL or the STARFlex devices.
CONCLUSIONS Modifications in 3 generations of devices have resulted in improved results for percutaneous
ASD closure. (J Am Coll Cardiol 2006;48:538–44) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.049Cardiology Foundation
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vranscatheter closure of secundum atrial septal defects
ASDs) is an attractive alternative to cardiac surgery now
ncreasingly performed and offered as primary therapy.
dvantages include the avoidance of sternotomy, cardiopul-
onary bypass, right atriotomy, postpericardiotomy syn-
rome, and longer hospitalization. Since first described (1),
arious devices have been designed and manufactured for
SD closure, with modifications over time aimed at im-
roving device deliverability and closure rates.
The Clamshell device (C.R. Bard Inc., Murray Hill, New
ersey) was studied in the U.S. and Canada from 1989 to
991 with initial favorable reports (2), but a high rate of late
evice arm fractures led to cessation of clinical trials. After
edesign and extensive preclinical evaluation, the second-
eneration CardioSEAL device (NMT Medical Inc., Bos-
on, Massachusetts) entered clinical trials in 1997, again
ith encouraging results (3). The third-generation STAR-
lex modification (NMT Medical Inc.) has a self-centering
From the Department of Cardiology, Children’s Hospital Boston, and Department
f Pediatrics, Harvard Medical School, Boston, Massachusetts. Children’s Hospital
oston received support for clinical trials from C.R. Bard, Inc. and NMT Medical,
nc., per patient enrollment, receives royalties for sales of CardioSEAL and STAR-
lex devices based on a licensing agreement with NMT Medical, Inc. Drs. Gauvreau
nd Jenkins have received honoraria for presenting data on NMT’s behalf.d
Manuscript received October 25, 2005; revised manuscript received March 7, 2006,
ccepted March 16, 2006.echanism consisting of flexible nitinol microsprings, and
ntered clinical trials in 1999.
The recent descriptions of several dozen late catastrophic
ardiac erosions after Amplatzer (AGA Medical Corp.,
olden Valley, Minnesota) ASD closure (4,5) have rekin-
led interest in alternate devices and techniques for closing
oles in the atrial septum. We have therefore reviewed the
utcomes and complications of 3 generations of closure
evices for simple ASDs at a single institution.
ETHODS
hildren’s Hospital Boston has over 15 years (6) of contin-
ous experience with transcatheter device closure of ASDs
nd other atrial defects. A review of prospective clinical
rials of device closures for simple ASDs was performed. In
he Clamshell trial, patients defined with simple ASD and
n the CardioSEAL and STARFlex trials the low-risk
atients were analyzed. Internal review board-approved
nformed consent was obtained for all cases.
Inclusion criteria were consistent for all trials: patient age
2 years, isolated secundum ASD, evidence of right ven-
ricular volume overload, evidence of shunt on transthoracic
chocardiogram (TTE), patients who were surgical candi-
ates for ASD closure, and a defect that was remote from
enous or valvar structures to permit safe seating of the
evice. The maximum stretched diameter permitted was 25
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August 1, 2006:538–44 ASD Closure by STARFlex Devicem for Clamshell, 20 mm for CardioSEAL, and 22 mm for
TARFlex devices.
Exclusion criteria were multiple atrial level shunts, unre-
aired associated cardiac defect, pregnancy, patients with
reviously implanted devices, intra-atrial thrombus, left
eart failure, concurrent atrial arrhythmias or antiarrhyth-
ia medication, aspirin intolerance, presence of significant
ulmonary hypertension (Wood units 5), endocarditis, or
igns of active infection/bacteremia.
Procedures were performed under general anesthesia with
ransesophageal echocardiogram (TEE) guidance of device
lacement. All patients were treated with 100 U/kg heparin at
he start of the case. Sufficient heparin was given to maintain
ctivated clotting times200 s (measured hourly). Prophylac-
ic Kefzol (vancomycin, if allergy) was given during the case,
nd a second dose was given 6 h later. Endocarditis
rophylaxis was recommended for 6 months after the
rocedure. Antiplatelet therapy of aspirin 1 to 3 mg/kg/day
as prescribed for 6 months after the device was placed for
ll patients.
The individual cardiologist performing the catheteriza-
ion was ultimately responsible for deciding the device size.
device-stretched diameter ratio of 1.7 to 2:1 was recom-
ended for the Clamshell and CardioSEAL devices. With
he addition of the self-centering mechanism a device-
tretched diameter ratio of 1.6 to 1.7:1 was recommended
or the STARFlex device. To deliver the device, an 11-F
heath was required for the Clamshell, a 10-F or 11-F for
he CardioSEAL, and a 10-F for the STARFlex device.
Data were collected from the prospective device database
nd study files, procedural catheterization and echocardiog-
aphy reports, and computerized department database. The
rocedural TEE assessed defect size and degree of sur-
ounding rims and the stretched diameter was measured by
ine angiograms of the sizing balloon waist. Patient age,
ody weight, device type and size, and device position were
ecorded. Malposition was defined as any device placed in an
ncorrect position and includes devices that were removed
uring the procedure (unreleased/released/embolized), re-
oved at surgery, or left in situ (device deemed stable and
lassified as incorrect final location).
Catheter-based complications were recorded and classi-
ed into minor, moderate, and severe categories. A minor
vent was defined as one that resulted in minimal or
ransient impairment that did not require any intervention,
.g., brief self-limiting arrhythmia. A moderate adverse
vent was defined as an event that caused a transient
mpairment that required an intervention to treat or correct/
Abbreviations and Acronyms
ASD  atrial septal defect
TEE  transesophageal echocardiogram
TTE  transthoracic echocardiogramrevent permanent damage, e.g., medication, cardioversion, hr device retrieval. A severe event was defined as life
hreatening, or causing permanent impairment or necessi-
ating significant intervention to prevent permanent dam-
ge, e.g., surgical management. Device fractures were re-
orded separately unless related to an adverse event.
Follow-up echocardiography was mandated by prospec-
ive protocols the day after and at a minimum either at the
-month or the 1-year follow-up. Clinical review was
equired at 1 month, 6 months, and 1 year (and 2 years for
he STARFlex cohort). The latest available follow-up was
ncluded when available. Fractures to the device at follow-up
ere examined by fluoroscopy and chest radiograph.
Residual flow was based on the most recently available
chocardiogram. No residual flow was defined as nil detect-
ble residual color flow through the defect. Trivial residual
ow was defined as a single color flow jet width 1 mm.
mall residual flow was a single color flow jet 1 to 2 mm and
ot of hemodynamic significance. Greater than small was
ny residual flow 2 mm. Multiple leaks were defined as
bove, i.e., “multiple, trivial” leaks was more than 1 leak,
ach of which had a color jet width of1 mm. The residual
ow was recorded as uncertain if no follow-up echocardi-
graphy was available or the acoustic windows did not allow
dequate interrogation of the atrial septum.
Successful outcomes were defined as a procedure that
esulted in no more than a small residual leak (2 mm), had
o severe complication related to device or procedure, and
ad no need for an additional device or surgery. A procedure
ith 2 mm residual leak, a severe adverse event, or the
eed for a second device or surgical procedure at any future
ime was defined as unsuccessful.
Patient and device characteristics were compared for the
groups of subjects receiving Clamshell, Cardio-
EAL, and STARFlex devices. A Fisher exact test for
ategorical variables and a Kruskal-Wallis test for continu-
us variables were performed. Proportions of successful
rocedures were compared for STARFlex versus the Am-
latzer Septal Occluder and surgical outcomes using the
isher exact test.
ESULTS
total of 72 Clamshell, 30 CardioSEAL, and 42 STAR-
lex devices were placed in uncomplicated ASDs. Table 1
hows the characteristics of the study sample; there is no
ignificant difference in gender, age, or weight at procedure
y device type. As expected, the earlier-generation device
as a longer period of follow-up.
The defect and device characteristics are shown in Table
. There is no significant difference between the sizes of
efects closed with each device. Because of the differing
uide for device sizing, as expected, the STARFlex device-
tretched diameter ratio was significantly smaller than the
ther 2 devices, with 60% of the STARFlex insertions
aving a device-stretched diameter ratio 2.
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ASD Closure by STARFlex Device August 1, 2006:538–44There is an increase in closure rates with each device
odification. None or trivial residual flow with each gen-
ration improves from 72% to 80% to 93% (Table 3).
Severe complications occurred in 5 Clamshell, 1 Cardio-
EAL, and 0 STARFlex patients; 4 Clamshell patients had
urgery: 2 embolizations, 1 mitral valve interference, and
ne late thrombus formation related to a fracture. The other
evere complication was an arm fracture with embolization to
he right ventricular free wall that was managed conservatively.
he CardioSEAL severe complication was a device emboliza-
ion to the right pulmonary artery noted on postprocedure
hest radiograph requiring surgical removal. A full list of
omplications is given in Table 4.
A summary of successful and unsuccessful outcomes is
hown in Table 5. The increasing percentage of successful
utcomes for each generation of device is 79%, 93%, and
8%, respectively (p  0.009). Differences in success rates
or Clamshell versus CardioSEAL versus STARFlex re-
ain after controlling for gender and age.
Fifteen (21%) patients in the Clamshell group had unsuc-
essful outcomes, 12 because of the need of a second procedure.
en patients had surgery, 4 for device-related complica-
ions, and 3 patients had a second device placed (1 patient
ad both a second device and surgery). Of the 9 patients
ith greater than small residual defect, 6 had a second
rocedure, and only 3 were medically managed.
Only 2 (7%) in the CardioSEAL group had an unsuc-
essful outcome. The first has been described in the previous
ext, and the second was a greater than small residual flow in
malpositioned device that was managed with a second
evice. In the STARFlex group, only 1 (2%) had a greater
han small residual leak shown by echocardiography, and no
atients had a second procedure or surgery. This case was a
Table 1. Study Sample
Clam
Date of implantation 2/89
Total patients 7
Male 18 (
Female 54 (
Median age at implantation, range (yrs) 6.6, 2
Median weight at implantation, range (kg) 23.9, 1
Median length of follow-up, range (yrs) 7.1, 0
NS  not significant.
Table 2. Atrial Septal Defect and Device Char
Clamshell
Device size (mm)
17 2 (3%)
23 4 (6%)
28 13 (18%)
33 29 (40%)
40 24 (33%)
Median stretch size, (mm) range 16 (6–25)
Device–stretch ratio, range 2.1 (1.6–4.1
Device–stretch ratio 2:1 32%*40-mm device not available after 2001.
N/A  not applicable.3-mm device that was placed in a defect with deficient rims
nd was positioned with 5 of the 8 arms on the right-hand
ide of the septum. No further intervention has been
equired.
Of the 144 patients in this study, there is a total of 596
erson-years of follow-up, with the Clamshell group having
he most follow-up. As noted previously, long-term com-
lications led to the cessation of clinical trials with the
lamshell device. The prospective trials of the Cardio-
EAL and STARFlex devices have 137 person-years of
ollow-up, with the latest complication (minor, transient
rrhythmia) occurring 1 month after device insertion. No
ate complications have been noted.
Deficient rims were not recorded for the Clamshell
roup, but procedural TEE reports show deficient rims in
7% (8 of 30) of CardioSEAL and 33% (14 of 42) of
TARFlex procedures. All were deficiencies of the retroaor-
ic (anterior) rim, with 1 case also having a deficient superior
im. Of these patients, 91% (20 of 22) had successful
utcomes with only 1 patient in each group, 40-mm
ardioSEAL embolization and STARFlex with 3- to
-mm residual shunt, having unsuccessful results.
Fractures are more common in the earlier-generation
evice, with fractures detected in 68% (47 of 69) of
lamshell, 41% (12 of 29) of CardioSEAL, and 34% (13 of
8) of STARFlex devices (p  0.001). Fluoroscopy of 67
evices was available in 29 of 30 CardioSEAL and 38 of 42
TARFlex devices, enabling further analysis. In this group,
5 fractures occurred, with 59% (19 of 32) of fractures in the
3/40-mm devices compared with 17% (6 of 35) for the
maller devices (p  0.001). When a fracture did occur,
uccessful outcomes still occurred in 92% (23 of 25) of cases.
l CardioSEAL STARFlex p Value
1 3/97 to 2/99 9/99 to 4/02
30 42
9 (30%) 14 (33%) NS
21 (70%) 28 (67%)
.8 10.8, 3.9–45.9 11.2, 2.1–66 NS
1.0 36.0, 14.5–88.6 34.2, 12.5–101.2 0.05
2.1, 1.0–4.0 2.0, 0–3.0 0.001
istics
CardioSEAL STARFlex p Value
1 (3%) N/A
3 (10%) 6 (14%)
13 (43%) 13 (31%) 0.02
6 (20%) 19 (45%)
7 (23%) 4* (10%)
14 (6–20) 16 (8–22) NS
2.1 (1.7–3.8) 1.9 (1.5–2.9) 0.001
13% 60% 0.001shel
to 9/9
2
25%)
75%)
.5–74
2.2–9
–13.9acter
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August 1, 2006:538–44 ASD Closure by STARFlex DeviceISCUSSION
he outcome of percutaneous device closure of uncompli-
ated ASDs in a single institution is reported with improved
Table 4. Complications
Severe
Embolization with need for surgery
AV valve interference
Embolization fractured arm
SVT, device thrombus related to fracture
Moderate
Malposition
Embolization
Incorrect final location
Access site complication
Air embolism
Allergy
Arrhythmia/palpitations
Brachial plexus injury
Chest pain
Decreased exercise tolerance
Delivery system malfunction
Fever/infection
Gastrointestinal
Headache
Other
Transient/neurologic symptoms
Minor
Access site complication
Air embolism
Allergy
Arrhythmia/palpitations
Chest pain
Decreased exercise tolerance
Device/delivery malfunction
Dizziness
Fever/infection
Gastrointestinal
Headache
Malposition
Other cardiac
Other
Pericardial effusion
Rash
Respiratory
Transfusion
Transient ST-segment elevation
Worsening congestive heart failure
Total patients/complication rates*
Severe
Moderate
Minor
Patients with more than 1 complication, graded according
able 3. Residual Flows at Most Recent Follow-Up
Clamshell CardioSEAL STARFlex p Value
esidual flow
None/trivial 52 (72%) 24 (80%) 39 (93%)
Small 11 (15%) 4 (13%) 2 (5%) 0.11
Greater than small 9 (13%) 2 (7%) 1 (2%)
otal 72 30 42AV  atrioventricular; SVT  supraventricular tachycardiautcomes for each generational modification. The latest-
eneration STARFlex device has excellent outcomes with
lmost universal success.
The first-generation Clamshell device was made of a
tainless steel frame with knitted Dacron fabric attached in
n umbrella-like fashion. There was only 1 joint per arm,
nd the device was available in 5 sizes: 17, 23, 28, 33, and
0 mm (Fig. 1). The second-generation CardioSEAL
evice entered clinical trials in 1997, after extensive redesign
o improve fatigue fracture resistance and spring-back.
lthough the sizes were identical to those of the Clamshell
lamshell CardioSEAL STARFlex
2 1
1
1
1
5 7 8
1 1
t recorded 6 3
1 1
1
1
5 2 2
1
1
1
1
3
2
7
3
3 2
1 2 2
1
2
7 1 4
10
2
4 1
1
2
5
1
2 1
1
5
1
1
4
1 1
1
1
5 (7%) 1 (3%) 0
9 (26%) 9 (30%) 11 (26%)
7 (24%) 2 (7%) 7 (17%)
hest degree.C
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ASD Closure by STARFlex Device August 1, 2006:538–44evice, the arms were made of a new metal alloy, different
ire diameter, and 2 joints per arm (Fig. 2). The third-
eneration STARFlex device entered clinical trials in 1999.
he major enhancements were a self-centering mechanism,
mproved pin-to-pin delivery, and a smaller delivery profile
Fig. 3). There were initially 4 sizes: 23, 28, 33, and 40 mm.
lthough there were no issues with the 40-mm device in
his trial of simple ASD closure, because of increased
mbolizations noted in other patients it was no longer
vailable after 2001.
The initial Clamshell trial from 1989 to 1991 was
iscontinued because of a high rate of fractures. Closure
ates and successful outcomes improved with the Cardio-
EAL device, which could be partly explained by superior
perator performance after the initial learning curve. Suc-
essful outcomes between the CardioSEAL and STARFlex
evices improved from 93% to 98% and were most likely
ttributable to device modifications, although by 1999
mproved experience among multiple operators also may
ave played a role. The different closure rates do not reach
tatistical significance, with the potential for a type 2 error
ith a small number of cases from a single institution. The
atest-generation device, with the addition of the self-
entering mechanism, not only provides the best closure
ates but also attains this result with significantly smaller
able 5. Results of Successful and Unsuccessful Procedures
Clamshell CardioSEAL STARFlex
urgery for device complication 4 1 0
urgery for residual shunt 6* 0 0
econd device 3* 1 0
nrepaired shunt 3† 0 1
ther major complication 1† 0 0
uccessful 57 (79%) 28 (93%) 41 (98%)
nsuccessful 15 (21%) 2 (7%) 1 (2%)
otal 72 30 42
 0.009; successful defined as 2 mm residual flow at the latest echocardiogram
nd no severe complication or repeat intervention. *One patient had a second device
nd surgery. †One patient had a residual shunt and a severe complication.Figure 1. Clamshell device.evice sizes. The prospective protocol recommended a
evice-balloon stretched diameter ratio of at least 1.7:1 for
he STARFlex device. This has resulted in excellent out-
omes and is recommended for future use.
The STARFlex modification is not approved or available
n the U.S. currently, and this report supports the availabil-
ty of this device for simple ASD when inserted by practi-
ioners adequately trained and familiar with the device. This
s particularly pertinent with the recent reports of late
erforations associated with the Amplatzer Septal Occluder
4,5). The data sets from all CardioSEAL and STARFlex
rials at this institution were reviewed, specifically looking
or erosions, perforations, effusions, or explants. We found
erosions or perforations after more than 900 device
mplantations: 2 in apical ventricular septal defects and 1 in
n ASD. In all 3 cases, the perforation of a single arm was
linically silent and was only discovered at the time of
ardiac surgery for a different indication.
omparison with previous reports. It is difficult to com-
are the Clamshell closure rates of this study with previously
ublished results because of different patient selection. The
arlier reports included defects associated with cyanotic
Figure 2. CardioSEAL device.Figure 3. STARFlex modification.
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August 1, 2006:538–44 ASD Closure by STARFlex Deviceeart disease, patent foramen ovale, and Fontan leaks.
ome et al. (2) reported a 63% closure rate (12 of 19) with
TE 6.5 months after placement; however, only 7 patients
n this series had an uncomplicated ASD. Boutin et al. (7)
ith 10 months of follow-up found a closure rate of only
7% in predominantly ASDs.
For CardioSEAL or STARFlex devices, these results
ompare favorably with the other published reports. A
ingle-institution report of the first 50 patients with a
ardioSEAL implant shows, at a mean of 9.9 months’
ollow-up, a small shunt in 46% of cases but right ventric-
lar dimensions returned to normal (8). There are limited
eports of the STARFlex device (9), but 1 study compares
he CardioSEAL and STARFlex devices. A total of 117
SD patients had 79 CardioSEAL and 38 STARFlex
evices placed, with significantly lower rates of residual
hunts with the STARFlex device (10).
The published outcomes for different percutaneous clo-
ure devices (11–14) and surgery (11,15–17) are summa-
ized in Table 6. Du et al. (11) use the same definition for
esidual leak on follow-up for the Amplatzer device and
rovide a complication list, enabling classification using the
ame criteria for both device and surgical patients. The
mplatzer Septal Occluder had severe complications in 5
atients of 442 (1.1%) who had a device attempt including
urgery for 4 embolizations and 1 heart block requiring
acemaker; 331 patients completed the 12-month follow-
p, with a successful closure rate of 98.5% (326 of 331).
owever, in the text there are 3 further spontaneous
losures; therefore, to be consistent with the present study,
he successful closure rate would be 99% (329 of 331) with
large residual shunt and 1 patient undergoing a second
evice placement. The surgical cohort has a 5.2% (8 of 154)
evere complication rate and follow-up on 149 patients with
Table 6. Published Results of Uncomplicated A
Number o
Patients
Comparison of ASD devices
Amplatzer (11) 442
Helex (12) 14
Sideris (13) 423
Das AngelWings (14) 14
Surgical results
Du et al. (11) 154
Berger et al. (15) 61
Galal et al. (16) 232
Pastorek et al. (17) 58
*Various definitions are used for residual shunts and are not
ASD  atrial septal defect; NR  not reported.
Table 7. Successful Outcomes: Comparison
Patient
Weight* (kg)
Defect
Size* (mm)
STARFlex 42.1 12.8
Amplatzer (11) 42.3 13.3
Surgery (11) 20.6 14.2*Mean values.quoted 100% closure rate, although only 72% of cases were
onfirmed by echocardiography and 28% were “assumed
losed.”
Comparison with the Amplatzer septal occluder was
erformed because it is the only device approved for use in
he U.S., and the same surgical group was used for both
evices. It is recognized that a direct comparison is not able
o be performed, especially for surgery, and also for device
nsertion because of the capability of the Amplatzer device
o close larger defects and to use smaller delivery sheaths. In
ny event, the comparison shows remarkable similarities
etween STARFlex and Amplatzer septal occluder devices
Table 7).
evice fractures. Device fractures were found to be less
requent in the newer generations of devices and also in the
maller devices. More frequent fractures in 40-mm Cardio-
EAL devices previously have been reported (10). The
resence of a fracture does not seem to impact on the
uccess of the procedure except in rare cases. Presumably
nce the device is endothelialized, the integrity of the repair
o longer requires the support of the arms of the device.
tudy limitations. The major limitation of the present
tudy is that the cohort of STARFlex patients is relatively
mall and cases were from a single institution, compared
ith the larger, multicenter Amplatzer and surgical cohorts
11). Residual leaks are documented by TTE, which is not
s accurate as TEE for documenting residual defects (7).
ome patients were referred from outside institutions, and
ata after completion of trial protocols were not available,
hich may underestimate closure rates because of ongoing
pontaneous resolution with time (7).
onclusions. Modifications in 3 generations of devices
nd increased procedural experience have resulted in signif-
cantly improved outcomes for percutaneous ASD closure.
Closure: Comparison of ASD Devices
Closure
Rates* (%)
Severe
Complications (%)
99 1.1
92 7.1
90 6.4
86 7.1
100 5.2
98 3.3
NR 6.0
92 3.4
d as 2 mm or 2 mm.
Closure
Rate (%)
Residual
Shunt (%)
Severe
Complication (%)
98 2 0
99 1 1
100 0 5SD
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ASD Closure by STARFlex Device August 1, 2006:538–44he STARFlex device provides excellent outcomes, with
ignificantly smaller device sizes than the earlier-generation
evices, and compares favorably to published results of other
evices and surgery.
eprint requests and correspondence: Dr. Alan W. Nugent, Chil-
ren’s Hospital Heart Center, 6621 Fannin MC 19345-C, Houston,
exas 77030-2399. E-mail: awnugent@texaschildrenshospital.org.
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